SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for HealthLynked (HLYK) — Jul 15, 2022

HealthLynked Corp
Date: July 15, 2022 · CIK: 0001680139 · Accession: 0000000000-22-007485

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-266088

Date
July 15, 2022
Author
Michael Dent
Form
UPLOAD
Company
HealthLynked Corp

Letter

United States securities and exchange commission logo July 15, 2022 Michael Dent Chief Executive Officer HealthLynked Corp 1265 Creekside Parkway, Suite 302 Naples, Florida 34108 Re:HealthLynked Corp Registration Statement filed on Form S-1 Filed July 11, 2022 File No. 333-266088 Dear Dr. Dent: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jordan Nimitz at 202-551-5831 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Clayton E. Parker, Esq.

Show Raw Text
United States securities and exchange commission logo
July 15, 2022
Michael Dent
Chief Executive Officer
HealthLynked Corp
1265 Creekside Parkway, Suite 302
Naples, Florida 34108
Re:HealthLynked Corp
Registration Statement filed on Form S-1
Filed July 11, 2022
File No. 333-266088
Dear Dr. Dent:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jordan Nimitz at 202-551-5831 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Clayton E. Parker, Esq.